TOTAL: $4.5M | ||||
Year to Date: $460.07M | ||||
Company |
Partner |
Amt. |
Triggering |
Details (Date) |
Abraxis |
Taiho Pharmaceutical Co. Ltd. (Japan) |
$3 |
Milestone payment |
Triggered by initiation of a Phase I trial in Japan of the cancer drug Abraxane; Taiho has rights to the drug in Japan (7/13) |
Memory |
F. Hoffmann- La Roche Ltd. (Switzerland) |
N/A |
Preclinical milestone |
Memory achieved preclinical milestones in their deal on nicotinic alpha-7 receptor agonists, triggering a commitment from Roche for $2.3M in research funding in 2007 (7/17) |
Neovacs SA* |
Debiopharm SA (Switzerland) |
ND |
Milestone payment |
Triggered by progress in their deal to develop a tumor necrosis factor-alpha kinoid for treating wasting syndromes (7/11) |
Predix |
Cystic Fibrosis Foundation Therapeutics Inc. |
ND |
Milestone payment |
Triggered by progress in program on the CFTR ion channel protein, which is the subject of an agreement between the parties (7/13) |
Renovis |
Pfizer Inc. |
$1.5 |
Milestone payment |
Triggered by nomination of a candidate from their VR1 collaboration for IND-enabling studies (7/27) |
|
| ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Private company. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
To read more on related topics, click on one of the words below.